Streptococcal toxic shock syndrome due to Streptococcus dysgalactiae subsp. equisimilis from retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: A case report.
Sho FujimotoYoshihiro EriguchiRinto NakamuraSota KamikawaAkiko YonekawaNoriko MiyakeNobuyuki OnoHiroaki NiiroPublished in: Modern rheumatology case reports (2024)
A 53-year-old man with adult-onset Still's disease developed severe streptococcal toxic shock syndrome (STSS) due to Streptococcus dysgalactiae subsp. equisimilis (SDSE), following retroperitoneal panniculitis. He was receiving tocilizumab (TCZ), an interleukin-6 receptor inhibitor. The modifying effect of TCZ on the immune response and the pathophysiology of SDSE infection may have led to retroperitoneal panniculitis and atypical STSS with delayed shock and flare of soft tissue inflammation.
Keyphrases
- immune response
- soft tissue
- robot assisted
- biofilm formation
- candida albicans
- rheumatoid arthritis
- oxidative stress
- case report
- early onset
- juvenile idiopathic arthritis
- binding protein
- pseudomonas aeruginosa
- rheumatoid arthritis patients
- dendritic cells
- escherichia coli
- cystic fibrosis
- inflammatory response
- drug induced